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Abstract
APE1 is a multifunctional protein possessing DNA repair and redox activation of transcription factors. Blocking
these functions leads to apoptosis, antiangiogenesis, cell-growth inhibition, and other effects, depending on
which function is blocked. Because a selective inhibitor of the APE redox function has potential as a novel
anticancer therapeutic, new analogues of E3330 were synthesized. Mass spectrometry was used to characterize
the interactions of the analogues (RN8-51, 10-52, and 7-60) with APE1. RN10-52 and RN7-60 were found to react
rapidly with APE1, forming covalent adducts, whereas RN8-51 reacted reversibly. Median inhibitory concen-
tration (IC50 values of all three compounds were significantly lower than that of E3330. EMSA, transactivation
assays, and endothelial tube growth-inhibition analysis demonstrated the specificity of E3330 and its analogues
in blocking the APE1 redox function and demonstrated that the analogues had up to a sixfold greater effect than
did E3330. Studies using cancer cell lines demonstrated that E3330 and one analogue, RN8-51, decreased the cell
line growth with little apoptosis, whereas the third, RN7-60, caused a dramatic effect. RN8-51 shows particular
promise for further anticancer therapeutic development. This progress in synthesizing and isolating biologically
active novel E3330 analogues that effectively inhibit the APE1 redox function validates the utility of further
translational anticancer therapeutic development. Antioxid. Redox Signal. 14, 1387–1401.
Introduction
Cellular response to DNA base damage is a highlyregulated, complex biologic process. APE1=Ref-1 (also
called HAP-1 or APEX, and here referred to as APE1) is a vital
protein that acts both as a DNA-repair enzyme and as a redox
signaling molecule, contributing to genomic maintenance in
mammals. Since it was identified in 1991 as a DNA-repair
enzyme and, in 1992, as a reduction-oxidation (redox) factor,
APE1has been the subject ofmore than350 articles. Specifically,
APE1 is a dual-function protein: (a) the major apurinic-
apyrimidinic endonuclease in base excision repair (BER) path-
ways of DNA lesions, and (b) a redox factor regulating eu-
karyotic gene expression. Although most research has focused
on its DNA-repair function, more-recent work has involved
characterizing its redox function (1, 9, 11, 17, 18, 28, 36–40).
APE1 is a redox coactivator of many transcription factors,
including the early growth response protein-1 (Egr-1), nuclear
factor-kB (NF-kB), p53, hypoxia-inducible factor (HIF-1a),
CREB, AP-1, and others in different cell systems (Fig. 1) (1,
4–7, 9, 13, 27). APE1 exhibits an a,b sandwich fold that includes
two pseudosymmetric central b sheets with surrounding a-
helices (18, 19), comprising a single folded domain. Both the
repair and redox activities reside within this domain, in-
cluding residues 40–318; the N-terminal 40-amino-acid resi-
dues are disordered and are not required for either function
(9, 18). Although the divalent metal ion-dependent reaction
by which APE1 catalyzes cleavage of the DNA backbone 50 of
the abasic site has been detailed (20, 21), the mechanism for
the redox activity has not yet been elucidated. What is known
about the redox activity of APE1 is that Cys 65 is critical for
the activity and that other Cys residues are likely involved (9).
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We have proposed that the redox activity of APE1 involves an
alternate conformation of the enzyme (9, 18).
APE1 demonstrates altered levels of expression in many
cancers, including pancreatic, multiple myeloma, breast,
prostate, ovarian, cervical, germ cell tumors, gliomas, osteo-
sarcomas, rhabdomyosarcomas, and non–small cell lung can-
cer (2, 12, 14, 23–25, 29, 35). HighAPE1 expression is associated
with chemo=radiotherapy resistance, poor outcomes, incom-
plete therapeutic responses, shorter relapse-free intervals,
shorter survival times, andaccelerated angiogenesis (2, 12, 14–28).
Reduced levels of APE1 in pancreatic lines alter HIF-1a activity
and increase sensitivity to gemcitabine (16, 38, 39). Therefore,
inhibition or alteration of the APE1 function—particularly its
redox function—in cancer cells can affect both tumor cell
growth and the tumor microenvironment (17, 18, 38, 39).
To isolate and study the role of redox regulation byAPE1 in
cancer cells, we have available to us a novel quinone deriva-
tive, E3330 (Fig. 1) (10, 19, 22, 26). While searching for NF-kB
inhibitors, it was determined that E3330 is highly selective in
inhibiting APE1 redox function and blocking the ability of
APE1 to convert various transcription factors (TFs) from an
oxidized, inactive state to a reduced, active state (Fig. 1) (10).
Far-Western blots and binding assays between radiolabeled
E3330 and proteins renatured on membrane blots demon-
strated that 14C-labeled E3330 selectively bound to both
recombinant APE1 and purified APE1 from cell nuclear
extracts (26).
Presently only a few compounds reportedly inhibit APE1
redox activity: E3330 and a series of quinones that exhibit
micromolar inhibition (22). From themany benzoquinone and
naphthoquinone analogues of the APE1-inhibitor E3330 that
were synthesized (22), three stand out as having the most
interesting potential for biologic studies and as providing the
clearest demarcation for a structure–activity relation (SAR)
approach to new analogue development; their properties are
described here. They were designed and synthesized to ex-
plore (a) inhibition of cell growth, and (b) structural changes
caused by redox regulation, the major biologic effect of in-
hibiting APE1 redox activity (17, 22). Additionally, redox in-
hibitors can be used as therapeutics or novel tools for
separating the APE1 DNA-repair activity from its redox
function in in vitro and cellular studies.
Materials and Methods
Reagents
E3330 and its analogues (RN8-51, RN10-52, and RN7-60)
were synthesized as previously described, as was RN7-58
(17, 22). Resveratrol was purchased from Sigma-Aldrich (St.
Louis, MO).
FIG. 1. Small-molecule inhibition of APE1 redox signaling activity. (A) Structure of E3330. (B) Space-filling model of E3330
was produced by using the software Vida 3.0.0 from OpenEye Scientific Software, Inc. (Santa Fe, NM; www.eyesopen.com).
(C)APE1 interacts with downstream transcription factors (TFs) such as NF-kB, HIF-1a, CREB, FOS, JUN, and so on, converting
them from oxidized to reduced states, allowing them to bind to their target promoters and switch on the transcription of genes.
However, E3330 and analogues presented in this article interfere with this redox signaling by blocking the APE1 ability to
convert the oxidized TF to a reduced TF, thereby keeping the target gene transcription turned off. (For interpretation of the
references to color in this figure legend, the reader is referred to the web version of this article at www.liebertonline.com=ars).
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Expression and purification of proteins
Human APE1 delta 40 proteins were expressed and puri-
fied as previously described (9). Site-directed mutagenesis
with the Stratagene Quikchange kit (La Jolla, CA) was used to
introduce C99A, C138A, and C99A=C138A substitutions in
APE1 delta 40. Substituted APE1 delta 40 proteins were ex-
pressed and purified as described for APE1 delta 40 and
confirmed by DNA sequencing analysis.
To express and purify full-length APE1 (FL-APE1), an N-
terminal hexa-His- SUMO-fusion (Invitrogen, Rockville, MD)
was constructed. The fusion construct was transformed into
Rosetta (DE3) Escherichia coli (Novagen, Gibbstown, NJ),
grown in 3 L of LB media with 20 mg=ml kanamycin and
34 mg=ml chloramphenicol until the OD at 600 nm reached 0.6,
and then induced overnight with 1mM isopropyl thioga-
lactoside at 158C. The cultures were harvested by centrifu-
gation at 4,000 g for 30min, and the pellets were stored at
808C. Each cell pellet was resuspended in 20ml of 50mM
sodium phosphate buffer, pH 7.8, 0.3 M NaCl, 10mM imid-
azole, and then lysed by using a French press (SLM-AMIN-
CO; Spectronic Instruments, Rochester, MN) at 1,000 psi. The
suspension was centrifuged at 35,000 rpm for 35min, and the
supernatant was then loaded on an Ni-NTA column at 48C.
The column was washed with 20 column-volumes of 50mM
sodium phosphate buffer, pH 7.8; 0.3 M NaCl, 20mM imid-
azole protein, and then incubated overnight with the SUMO-
specific protease Ulp1 added at a molar ratio of *1:1,000
(Ulp1=FL APE1). Full-length APE1 was then eluted from the
column in the same buffer and further purified by using an S-
Sepharose column (GE Healthcare, Piscataway, NJ) run in
50mM MES, pH 6.5, 1mM DTT, and a linear NaCl gradient
(0.05–1 M). The peak fractions were then combined, concen-
trated, and subjected to gel filtration chromatographic sepa-
ration by using a Superdex 75 (GE Healthcare) in 50mM Tris,
pH 8.0, 0.1 M NaCl. Fractions containing full-length APE1
were then concentrated by using Amicon Ultra centrifugal
concentrators (Millipore, Billerica, MA) and stored at 808C.
Cloning, protein expression, and purification of human
thioredoxin. The gene encoding human thioredoxin (TRX)
was cloned into pET15b vector with restriction endonucleases
NdeI and BamHI and confirmed by DNA sequencing. Protein
was expressed in E. coli Rosetta after induction with 1mM
isopropyl b-d-thiogalactoside (IPTG) induction overnight at
188C. The cells were harvested by centrifugation and frozen at
808C. Frozen cells were thawed and resuspended in lysis
buffer (50mM phosphate buffer, pH 7.8, 0.3 M NaCl, 10mM
imidazole) and lysed byusing a Frenchpress. The recombinant
protein was purified by Ni-nitrilotriacetic acid (Ni-NTA) col-
umn chromatography and Q-sepharose column chromatog-
raphy in 50mM Tris-HCl, pH 8.5, with a linear NaCl gradient.
Thrombin was added to the eluted sample overnight at 48C to
remove the N-terminal histidine tag, resulting in human TRX
protein with three extra amino acids G-S-H at its N-terminal.
The protein was finally purified by Q-sepharose column
chromatography in 50mM Hepes, pH 7.5, with a linear NaCl
gradient. The final product is one band on SDS-PAGE.
APE1-repair assays. Oligonucleotide gel-based APE1
endonuclease activity assays were performed as previously
described (6, 15).
Cell-survival=killing assays. The 3-(4, 5-dimethylthiazol-
2-yl)-5-(3-carboxymeyhoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTT) dye assays for cell growthwere performed
as previously described (6, 32).
Mass Spectrometric Analysis
Global ESI-QTOF Experiments. Protein samples were
analyzed in thepositive-ionmode on aBrukerMaXisUHR-TOF
(ultra-high resolution time-of-flight) (Bruker Corp., Fremont,
CA). Capillary voltage was set at 3,600 V. Nebulizer pressure
was 0.4 bar, and dry gas was at 1.0 L=min. The drying tem-
perature was 1808C. The instrument was calibrated by using
Tuning Mix (Agilent Technologies, Santa Clara, CA) as the ex-
ternalmass calibrant. Spectral deconvolutionwas performed by
using MaxEnt with Data Analysis (provided by the manufac-
turer of the spectrometer). Reactions of protein and redox in-
hibitors were carried out at a 1:5 molar ratio of protein (100mM)
to ligands (500mM) in 10mM HEPES (Sigma, St. Louis, MO)
buffer at pH 7.5 at room temperature. Reactionswere quenched
on dry ice before mass spectrometry (MS) analysis. Typically,
200–300pmolofprotein sampleswere loadedon anOpti-Guard
C18 column (101mm i.d.; Cobert Associates; St. Louis, MO)
fordesalting and then eluted tomass spectrometer byusing 50%
(vol=vol) acetonitrile with 0.1% formic acid (FA) at 10ml=min.
The percentage of difference species for analysis of RN8-51 re-
action with APE1 was estimated by the observed peak intensi-
ties based on the assumption that the ionization efficiency of the
protein molecule is not changed by the modification.
LC-MS=MS experiments
A 10-ml solution of APE1 (100 mM) and RN6-70, RN10-52, or
RN8-51 (500 mM) was incubated in 10mM HEPES (pH 7.5)
at room temperature for 0.5 h. DTT (protein=DTT¼ 1:20,
mol=mol) was added to quench the reaction. The sample was
diluted with water to a final concentration of 1mM. A portion
of the final diluted solution (50 ml) was submitted to trypsin
digestion (protein=trypsin¼ 50:1, wt=wt) at 378C for 4 h. The
solution was then analyzed with LC-MS=MS, whereby 5ml of
digestion solution was consumed for each experiment.
Reversed-phase capillary LC separations were performed
with an Eksigent NanoLC-1D pump (Eksigent Technologies
Inc.; Livermore, CA). The reversed-phase capillary column
(0.075150mm) was packed in house by using a PicoFrit tip
(New Objective Inc., Woburn, MA) with Magic C18 resin
(5-mm particles, 200 A˚ pore size; Michrom Bioresources Inc.,
Auburn, CA). The mobile phases consisted of water with
0.1% FA (A) and acetonitrile with 0.1% FA (B). Immediately
after sample loading, the mobile phase was held at 98%
A for 12min. A linear gradient was performed by using 2% to
60% solvent B over a 60-min period, then to 80% solvent
B over a 10-min period at 260 nl=min, followed by a 12-min
re-equilibration step by 100% solvent A. The flow was di-
rected by a PicoView Nanospray Source (PV-550; New Ob-
jective) to the LTQ Orbitrap XL mass spectrometer (Thermo
Fisher Scientific Inc., San Jose, CA). The spray voltage was
1.8–2.2 kV, and the capillary voltage was 27 V. The conven-
tional data-dependent MS=MS acquisition method was used
with the Xcalibur 2.0.7 control system, in which full spectra
were collected over the range of m=z 350–2,000 followed by
product-ion (MS=MS) spectra of the six most abundant ions.
The full mass spectra of the peptides were acquired at high
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mass-resolving power (60,000 for ions of m=z 400) with the FT
analyzer. The six most abundant precursor ions were dynam-
ically selected in the order of highest to lowest intensity
(minimal intensity of 1,000 counts) and subjected to collision-
induced dissociation (CID) at a normalized collision energy of
35% of the maximum available. Precursor activation was per-
formed with an isolation width of 2 Da and an activation time
of 30ms. The automatic gain control target valuewas regulated
at 1106 for FT and 3104 for the ion trap, with a maximum
injection timeof 1,000msand200ms for the FTand the ion trap,
respectively. The instrumentwas externally calibrated by using
a standard calibration mixture of caffeine, the peptide MRFA,
and Ultramark 1621 (Thermo Fisher Scientific). To identify
covalent modifications, LC-MS=MS data were searched with
Mascot 2.2 (Matrix Science, London, UK). Parameters used for
Mascot were: enzyme, trypsin; maximum missed cleavage, 3;
peptide mass tolerance, 10 ppm with one 13C peak; peptide
charge, þ1 to þ3; product mass tolerance, 0.6 Da; instrument
type, default (searching for all types of b and y ions).
Redox assays
Electrophoretic mobility shift assay. Increasing amounts
of E3330 or its analogues (RN8-51, RN10-52, and RN7-60)
were incubated with 2ml purified hAPE1 or thioredoxin (re-
duced with 1.0mM DTT, then diluted to 2 mg=ml with 0.2mM
DTT in PBS) in EMSA reaction buffer [10mM Tris (pH 7.5),
50mM NaCl, 1mM MgCl2, 1mM EDTA, 5% (vol=vol) glyc-
erol] with a total volume of 10ml for 30 h. Then EMSA was
performed, as previously described (17).
Transactivation assays. The established, stable Skov-3X
ovarian cancer cells with NF-kB Luc gene (luciferase gene
with the NF-kB–responsive promoter) (Stratagene, La Jolla,
CA) (17) were treated with increasing amounts of E3330 or its
analogues (RN8-51, RN10-52, and RN7-60) for 40 h. The cells
were lysed; then Firefly luciferase activities were assayed
using the Luciferase Reporter Assay System (Promega Corp.,
Madison, WI) in a 96-well microtiter plate luminometer
(Thermo Lab Systems, Franklin, MA) and were normalized to
the cell numbers measured by MTT assay (5). All of the ex-
periments were performed in triplicate and then repeated at
least three times in independent experiments.
Matrigel tube-formation assay. This assaywas performed
as previously described (17). In brief, Matrigel (BD Bios-
ciences) was used to coat each well (50ml) of a precooled 96-
well plate. Retinal vascular endothelial cells (RVECs) at 5,000
cells perwell were seeded and incubated in EBMwith 1% fetal
bovine serum and 10 ng=ml basic fibroblast growth factor at
378C for 24 h. The formation of capillary-like structures by
RVECs on the basement membrane matrix (Matrigel) was
quantified by counting the number of closed tube units in each
well. The percentage of the tube formation to the vehicle
control group was calculated for each treated group (n¼ 3).
TdT-mediated dUTP-fluorescein nick-end labeling (TUNEL).
The TUNEL assay allows us to determine the percentage of
cells undergoing apoptosis. The reactions were performed
according to the manufacturer’s protocol (Roche, In-
dianapolis, IN). Random fields of cells were photographed
under phase microscopy and scored as percentage positive
cells for the terminal transferase labeling reaction.
Statistical analysis
Quantitative data were obtained from at least three inde-
pendent experiments and expressed as the mean SD. Sta-
tistical significances of differences between two groups were
determined by using Student’s t test. Statistical significance is
as indicated in the figure legend.
Results
New and novel E3330 analogues block APE1
redox function
We previously demonstrated that E3330, a molecule bind-
ing specifically to APE1, blocks only the redox function of
APE1 and interferes with its ability to convert a variety of
transcription factors from an oxidized to a reduced state,
which affects their ability to bind to their target DNA and
‘‘switch on’’ respective genes (17, 22). E3330 has no demon-
strable effect on APE1-repair endonuclease activity (17, 22).
Additionally, our data (and those of others) show that E3330
blocks angiogenesis in a variety of in vitro and in vivomodels
(17, 38, 39), demonstrating implications for angiogenic indi-
cations, including cancers and age-related macular degener-
ation (17). However, we also are interested in developing new
analogues of E3330, not only to achieve sub-micromolar levels
of activity, but also to help us determine the mechanism(s) by
which E3330 interacts with and blocks APE1 redox function,
which is still unknown (17, 18).
We recently published the results of synthesizing a number
of novel E3330 analogues (22); here we present data on three
of the most promising compounds. In a series of experiments
using EMSA, as described previously (17), we determined
that analogues RN8-51, RN10-52, and RN7-60 had redox-
blocking effects similar to that observed for E3330. Interest-
ingly, the IC50 values for these compounds were at least 10
times lower than that of E3330 (20 mM): RN8-51 was 0.5 mM,
RN10-52 was 0.75 mM, and RN7-60 was 1.5 mM, by using AP-1
as the transcription factor target complex (Fig. 2). Both RN8-
51 and RN10-52 were active at the sub-micromolar level. By
comparison, an important role for the quinone moiety was
established through characterization of RN7-58, in which the
naphthoquinone core is replaced by a dimethoxynaphthalene
core. RN7-58 shows no effect on APE1 redox activity in EMSA
analysis (Fig. 2D). Similarly, a previously reported inhibitor of
APE1 redox activity, resveratrol, as shown in Fig. 2A, shows
no inhibitory effect on APE1 redox function, even at concen-
trations as high as 200mM. We did not observe any inhibitory
effect of resveratrol on APE1-repair activity (data not shown).
To pursue further the specificity of E3330 and these three
analogues as APE1 redox inhibitors, we also used EMSA to
test the ability of the compounds to inhibit reduction of
transcription factors by thioredoxin, an important cellular
redox protein. Although APE1 is the relevant redox factor for
AP-1 in vivo, thioredoxin will reduce AP-1 in vitro (EMSA
redox assay). As demonstrated in Fig. 3, increasing amounts
of E3330, RN8-51, and RN10-52 decreased the ability of APE1
to enhance AP-1 DNA-binding but did not similarly affect the
thioredoxin redox activity (panels A and B). In contrast, RN7-
60 affected the abilities of both APE1 and thioredoxin to
enhance AP-1 DNA binding (Fig. 3C). From these data, we
concluded that E3330, RN8-51, and RN10-52 specifically
blocked the redox activity of APE1 but did not affect thio-
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redoxin. RN7-60 blocked the redox activity of both, but
slightly more so with APE1 than with thioredoxin. This sug-
gests that E3330, RN8-51, and RN10-52 are specific for APE1,
whereas RN7-60 appears to be a more promiscuous redox
inhibitor.
Effect of E3330 and analogues on APE1-repair
endonuclease function
In the past, we demonstrated that E3330 has no effect on the
DNA-repair endonuclease activity of APE1 (1, 17). As shown
FIG. 2. E3330 analogues blocked APE1 redox function in EMSA assay. Increasing amounts of E3330 or its analogues
(RN8-51, RN10-52, and RN7-60) were incubated for 30min with 2ml purified hAPE1 (reduced with 1.0mM DTT, then diluted
to 2mg=ul with 0.2mM DTT in PBS) in EMSA reaction buffer [10mM Tris (pH 7.5), 50mM NaCl, 1mM MgCl2, 1mM EDTA,
5% (vol=vol) glycerol] with a total volume 10 ml. EMSA was performed with reduced APE1 and 0.02mM DTT, which was the
amount of DTT carried over from the reduction of APE1 as control. (A) RN8-51; (B) RN10-52, and B) RN7-60 inhibited AP-1
DNA-binding enhanced by APE1 in a dose-dependent manner, with a much lower IC50 (0.5, 0.75, and 1.5 mM, respectively)
than E3330 (20 mM). Increasing amounts of resveratrol (C) or analogue RN7-58 (D) were incubated for 30min with 2ml
purified human APE1 (reduced with 1.0mM DTT, and then diluted to 2 mg=ul with 0.2mM DTT in PBS) in EMSA reaction
buffer [10mM Tris (pH 7.5), 50mM NaCl, 1mMMgCl2, 1mM EDTA, 5% (vol=vol) glycerol] with a total volume 10ml. EMSA
was performed with unreduced APE1 and 0.02mM DTT, which was the amount of DTT carried over from the reduction of
APE1 as control. Neither compound showed any inhibitory effects. Experiments were repeated 3 times with similar results, as
shown.
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FIG. 3. Effect of E3330 analogues on APE1 and thioredoxin redox function. Increasing amounts of E3330 or its analogues
(RN8-51, RN10-52, and RN7-60) were incubated for 30min with 2 ml purified human APE1 or thioredoxin (reduced with
1.0mM DTT, then diluted to 2mg=ml with 0.2mM DTT in PBS) in EMSA reaction buffer with total volume of 10 ml. The EMSA
assay was performed as described in Methods. E3330 (A–C), RN8-51 (A), and RN10-52 (B) blocked the redox activity of APE1
but not thioredoxin. RN7-60 (C) blocked the redox activity of both, but affected APE1 more than thioredoxin.
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in Fig. 4, none of the analogues blocked APE1-repair endo-
nuclease activity, even at concentrations up to 10 times higher
than those used in the EMSA experiments. These data dem-
onstrate the specificity of these analogues for the redox—but
not the repair—function of APE1.
E3330 analogues block APE1 redox signaling in cells
To determine whether the analogues will block the redox
function of APE1 in cells (rather than just in cell-free assays),
we investigated the ability of the analogues to block APE1
redox activity in a cell-based, transactivation assay, as used
previously for E3330 (18). In this assay, an NF-kB binding
sequence upstream of a luciferase reporter was stably ex-
pressed in ovarian cancer cell line SKOV-3X. Increasing
amounts of E3330 and the analogues all decreased the ability
of NF-kB ability to bind to the promoter (Fig. 5) in a dose-
dependent manner. RN8-51, RN10-52, and RN7-60 had more
than 3 times the effect that E3330 had on NF-kB activation in
this assay. IC50 values for E3330, RN8-51, RN10-62, and RN7-
60 were 80, 27, 12, and 25mM, respectively. The results of this
in vitro assay indicate that, in cellular studies, the analogues
have the potential to block APE1 redox function more effi-
ciently than E3330 can.
E3330 and analogues inhibit
growth of ovarian cancer cell lines
Whereas APE1 plays an important role in cell growth and
survival through its repair and redox functions, it is becoming
apparent that the redox function of APE1 is more involved in
cell growth and angiogenesis activities, whereas the re-
pair activity is more highly attuned to cellular death (5, 17, 18,
38–40) Thus, the APE1 repair function helps prevent the
triggering of apoptosis (5, 27, 28, 30), whereas APE1 protein-
to-protein interactions help promote cellular proliferation.
Previous studies in normal dividing cells and in neuronal cells
(data not shown) do not indicate an effect of the APE1 redox
function on cell survival (8, 11, 31). However, by using a cell-
growth assay, we demonstrated that E3330 and the three
analogues decreased the growth of both the ovarian SKOV-3X
and Hey-C2 cell lines (Fig. 6). RN10-52 and RN7-60 had up to
a sixfold greater inhibitory effect than E3330 did. In Skov-3X
cells, the LD50 of RN10-52 and RN7-60 were 8.3 mM and
21.8 mM, respectively, whereas E3330 was 44.1 mM. In Hey-C2
cells; the LD50 values of RN10-52 andRN7-60were 6.7 mM and
15mM, respectively, in contrast to that of E3330,38.9mM. RN8-
51 had an effect similar to E3330: LD50 of 44.1 mM versus
55.9 mM in Skov-3X cells, respectively, and 40mM versus
38.9 mM in Hey-C2 cells. These results indicate that these an-
alogues do have cell-growth inhibitory effects on cancer cell
lines.
In vitro Matrigel tube-formation assays:
angiogenesis studies
We performed in vitro Matrigel tube formation assays to
determine whether E3330, RN8-51, RN10-52, and RN7-60
would block endothelial tube formation, as described in
Methods (Fig. 7). Early-passage (2–4 days) umbilical cord
blood-derived erythroid–colony-forming units cells (ECFCs)
were treated with vehicle only or with varying concentrations
of E3330, RN8-51, RN10-52, or RN7-60. Low-magnification
images were captured and scored to quantitate the total
FIG. 4. Effect of E3330 analogues on APE1 endonuclease activity. Oligonucleotide gel-based APE1 endonuclease activity
assays were performed as described in Methods (8,15). The upper band (26 mer) represents uncleaved AP oligonucleotides,
whereas the lower band (14 mer) is the reacted oligonucleotide. E3330, RN8-51, RN10-52, and RN7-60 had no effect on APE1
endonuclease activity. (For interpretation of the references to color in this figure legend, the reader is referred to the web
version of this article at www.liebertonline.com=ars).
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FIG. 5. E3330 analogues inhibited APE1 redox activity in transactivation assay. Increasing amounts of E3330 (A) or its
analogues (RN8-51 (B), RN10-52 (C), and RN7-60 (D)) were added to SKOV-3X ovarian cancer cells with pNF-kB-Luc. After
40 h of treatment, luciferase activity was measured, and MTT assays were performed to measure cell numbers. The ratio of
luciferase activity to MTT activity was determined to measure NF-kB activity. Data are expressed as the mean SEM of three
independent experiments performed in duplicate and are presented as percentage transactivation compared with control of
no E3330 or E3330 analogues.
FIG. 6. Effect of E3330 analogues on cell growth=survival in two ovarian cancer cell lines.MTT assays were performed as
described in Methods. Increasing amounts of E3330 and analogues resulted in decreased cell growth and decreased cell
numbers in both cell lines. Analogues RN7-60 and RN10-52 had a greater effect than E3330 did; RN8-51 had an effect similar
to that of E3330. Data are expressed as the mean SEM of three independent experiments performed in triplicate.
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number of closed network units formed per well, and then
normalized to the amount of closed-unit formation in the
vehicle control. A significant decrease ( p< 0.001) in closed-
network tube formation was observed at 7.5 mM for E3330,
25 mM for RN8-51, 5mM for RN10-52, and 10 mM for RN7-60–
treated ECFCs (Fig. 7A and B).
Endothelial cell TUNEL assays
We also performed the TUNEL assay on ECFCs to deter-
mine the percentage of cells undergoing apoptosis. We wan-
ted to determinewhether the ablation of tube formation in this
assay was due to inhibition of the tube-formation process
instead of cell death. As shown (Fig. 7C), E3330 and RN8-51
did not induce any apoptosis in the cells, but hydrogen per-
oxide, our positive control, was very TUNEL positive. How-
ever, we did see some increase in apoptosis with RN10-52 and
a dramatic apoptotic response with RN7-60. From these data,
we conclude that E3330 and RN8-51 are not inducing cell
killing through apoptosis.
MS analysis of the interaction of E3330
and analogues with APE1
To assess how and to what extent E3330 and its analogues
react with APE1, an ESI-MS analysis was performed for a 1-
min reaction of FL-APE1 and a mixture of RN7-60, RN10-52,
RN 8-51, and E3330. The results were based on the assump-
tion that the effect ofmodifications on the ionization efficiency
is negligible. As shown in Fig. 8, covalent adducts of RN7-60
and RN10-52 with APE1 were identified in the global MS
analysis, suggesting that these compounds have the highest
reactivity after 1min. The peak intensities for RN7-60– and
RN10-52–modified FL-APE1 were similar (Fig. 8), suggesting
that they have a similar reactivity to the protein. Modifica-
tions corresponding to one to seven additions were observed
for the reactions of FL-APE1 and RN7-60 and RN10-52 after
0.5 h, respectively (Fig. 9).
After a 1-h reactionwith RN8-51, about 50% and 20% of FL-
APE1 was modified on single and double sites, respectively
(Fig. 9). No modification of FL-APE1 by E3330 was observed
FIG. 7. In vitro Matrigel tube formation and TUNEL
apoptosis analysis of ECFCs. (A) E3330 and analogues
impair the ability of ECFCs to form tubes in a dose-
dependent manner. A significant decrease (**p< 0.001) in
closed network tube formation was observed at 7.5 mM for
E3330, 25mM for RN8-51, 5mM for RN10-52, and 10mM for
RN7-60. (B) Representative pictures of dose-dependent
tube-formation ablation in ECFCs treated with E3330. (C)
ECFCs were treated with E3330, RN8-51, RN10-52, and
RN7-60, stained and analyzed with flow analysis for
TUNEL-positive cells. Cells were treated with 1mM H2O2
as a positive control. The vehicle control-treated cells were
0.5% EBM-2 cells treated only with media and DMSO. No
increase in apoptosis was noted with E3330- and RN8-51–
treated cells. A dose-dependent increase in apoptosis was observed in the RN10-52–treated cells, but the increase at 5 and
10 mM did not differ significantly from the vehicle control (DMSO)-treated cells. ECFCs treated with as little as 2.5 mM RN7-60
were almost entirely TUNEL positive. Statistical analysis was performed as described in Methods. (**p< 0.01 in C).
NOVEL APE1 REDOX INHIBITORS 1395
after a 2-h reaction. Similar results were observed for reactions
of APE1 delta 40 and E3330=analogues. After a 4.5-h reaction,
APE1 delta 40 was observed with two (*24%), three (*36%),
four (*28%), and five (* 11%)modifications by RN7-60, with
two (*68%) and three (*32%) modifications by RN10-52,
with one modification (*32%) by RN8-51, and with no
modification by E3330. The observed mass differences for
peaks corresponding to adducts of RN7-60 (276 Da) and
RN10-52 (319 Da) with APE1 in Figs. 8 and 9 or APE1 delta 40
correspond to mass increases of 240 Da and 283 Da, respec-
tively, consistent with the loss of HCl (36 Da). However, the
observed mass difference for RN8-51 (272 Da) adducts with
APE1 or APE1 delta 40 is 274 Da, consistent with no loss of
substituent moieties from RN8-51. Formation of the observed
products is consistent with a Michael addition reaction, as
shown in Fig. 8B. LC-MS=MS analysis of the reaction products
obtained for RN7-60 and RN10-52 confirmed that these
compounds covalently modify Cys residues present in APE1.
However, no modified peptides were observed in the LC-
MS=MS analysis of RN8-51, suggesting that the modifications
of this protein are reversible.
To determine the sites of reactivity for RN8-51, APE1 delta
40 C99=138A, C99A, andC138Awere reactedwith RN8-51 for
3 h. These mutants were selected to determine whether RN8-
51 reacts with the solvent-accessible Cys residues C99 or C138
or both. No modification was observed for the reaction with
the C99A=C138A protein, one modification for C99A protein,
and one modification for C138A protein (Fig. 10). Thus, we
conclude that RN8-51 reacts with the two solvent-accessible
cysteines C99 and C138.
FIG. 8. ESI-MS analysis of APE1 with E3330 and analogues. (A) ESI spectra of FL-Ape1 and a mixture of ligands (RN7-60,
RN10-52, RN8-51, and E3330) after 1-min reaction, showing modifications by RN7-60 and RN10-52. P, FL-Ape1; *the water
adducts of the protein and ligand complexes. (B) Mechanism of covalent vs. reversible inhibition of APE1 redox activity.
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Discussion
We and others previously showed that E3330 specifically
blocks the APE1 redox signaling function without interfering
with its DNA-repair activity (17, 22). E3330 demonstrably
blocks angiogenesis through APE1 inhibition both in vitro and
in vivo (17, 38, 39) and affects pancreatic tumor xenograft cell
growth (Fishel laboratory; unpublished data). In using se-
lected E3330 analogues that we recently synthesized and re-
ported (22), these studies demonstrate the activity of three
additional APE1 redox inhibitors.
The overall goals of the studies presented here were to (a)
identify new APE1 redox inhibitors with lower IC50 values
than E3330, both in vitro and in cellular studies; and (b) use
these new chemical substances to determine better how E3330
and its analogues specifically block APE1 redox function. The
actual mechanism of action of APE1 redox activity has yet to
be elucidated (18). As presented here, we determined that the
in vitro redox IC50 of these three compounds is at least 10 times
lower than that of E3330, with RN8-51 and RN10-52 in the
sub-micromolar range and RN7-60 at 1.5 mM—all well below
E3330 at 20mM (Fig. 2). All of the compounds except RN7-60
were specific for APE1 redox inhibition (i.e., they did not affect
thioredoxin, whereas RN7-60 did), leading us to conclude that
RN7-60 is not an APE1-specific redox inhibitor (Fig. 3).
An important role for the quinone moiety in this series of
analogues was established through testing of the previously
synthesized analogue RN7-58 (22), the dimethoxynaphthalene
compound. RN7-58 did not show any inhibition even up to
100mM (Fig. 2D). As previously stated, none of the compounds
affected the AP endonuclease function of APE1, as expected
(Fig. 4).
Additionally, although it was previously reported that re-
sveratrol inhibits APE1 redox activity (34), we were unable to
replicate those findings, even at resveratrol concentrations
that were 5 times higher than those used previously (Fig. 2C).
This finding is significant, as resveratrol is a natural com-
pound with multiple reported activities; one is ascribed to
APE1 redox inhibition (3, 33).
Finally, we determined that all three compounds blocked
NF-kB activation in a dose-dependent manner, with all of the
analogues having more than 3 times the inhibitory effect of
E3330 in ovarian cancer cell lines (Fig. 6). Based on this cellular
in vitro assay, these results indicate that the analogues have
the potential to block APE1 redox function more efficiently
than E3330 in a biologic context.
FIG. 9. ESI-MS analysis of adduct formation. (A) ESI spectra of FL-APE1 and RN7-60 after 0.5-h reaction, showing
multiple (1, 2, 3, 4, 5, 6, and 7) modifications. (B) ESI spectra of FL-APE1 and RN10-52 after 0.5-h reaction, showing multiple
(1, 2, 3, 4, 5, 6, and 7) modifications. (C) ESI spectra of FL-APE1 and RN8-51 after 1-h reaction, showing 1 and 2 modifications.
P, FL-APE1; *the water adducts of the protein and ligand complexes; ^Unidentified peaks. (D) ESI spectra of FL-APE1 and
E3330 after 2-h reaction, showing no modifications by E3330. P, FL-APE1; *the water adducts of the protein and ligand
complexes; #contamination peaks due to the carryovers on the C18 column. ^Unidentified peaks. #Peaks correspond to a 44
from the adduct peak. This is the same loss as that going from NH(CH2)2OH to O
-, suggesting amide hydrolysis.
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Although we know that APE1 plays an important role in
cell growth and survival through its repair and redox func-
tions, it is becoming apparent that the APE1 redox function is
also important for angiogenesis (5, 17, 18, 38–40). We and
others observed the E3330 antiangiogenesis effects (17, 38, 39).
By using two angiogenesis assays, Matrigel tube formation
(Fig. 7) and aortic ring-formation assays (data not shown), we
observed a significant decrease in closed network tube for-
mation, an indicator of antiangiogenic properties with all
analogues, at levels similar to that observed for E3330 (Fig. 7).
For RN8-51 and E3330, these results are not due to cell killing.
However, RN10-52 did show some slight apoptotic effects at
its higher doses, whereas RN7-60 demonstrated a dramatic
apoptotic response at all doses tested. Therefore, RN8-51 ap-
pears to be the most promising of the new analogues.
Previous studies in normal dividing cells (stimulated
CD34þ human cells; data not shown) and in neuronal cells do
not indicate that the APE1 redox function affected cell sur-
vival (8, 11, 31). However, by using two ovarian cancer cell
lines, we demonstrate here that E3330 and the three analogues
decrease the growth of both cell lines (Fig. 7). RN10-52 and
RN7-60 have a greater effect than E3330, whereas RN8-51 has
an effect similar to that of E3330. These results are consistent
with the TUNEL data observed in the ECFCs and indicate that
RN8-51 diminishes cell growth in cancer cell lines, as ob-
served for E3330, but the effect is through cell-growth inhi-
bition, not apoptosis (Fig. 7C) (5, 17, 38, 39). In contrast, some
apoptosis was observed for RN10-52, whereas RN7-60 was
found to induce apoptosis in nearly 100% of the cells, even at
the lowest concentration used. Thus, the more-toxic effects of
RN10-52 and RN7-60 are potentially problematic for in vivo
studies, and preliminary toxicology and maximum tolerated
dose (MTD) studies in mice demonstrate that RN7-60 is toxic
to animals. This is not unexpected, given the promiscuous
nature of RN7-60. Preliminary studies with E3330 do not
show any toxicity up to 75mg=kg, no negative pathology, and
a half-life of 5.6 h in mice (data not shown).
To assess the nature of E3330 and the interactions of its
analogs with, and reactivity to APE1, we conducted an ESI
mass spectrometric analysis (Fig. 8). Both RN7-60 and RN10-
52 reacted rapidly with APE1, forming covalent adducts
through modification of Cys residues. Reacted individually,
FIG. 10. ESI mass spectra of ApeD40 and its mutants C99A, C138A, and C99=138A after reaction with compound RN8-51.
Mass spectra were collected on a Bruker MaXis UHR-TOF instrument, and deconvolution was done with the MaxEnt1
algorithm.
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both RN7-60 and RN10-52 resulted in þ1 to þ7 additions to
APE1. RN8-51 was less reactive but still formed covalent
adducts at levels of about 50% and 20% on single and double
sites, respectively (Fig. 9).
The sites of modification by RN8-51 were either Cys99 or
Cys138 or both, the two solvent-accessible Cys residues, al-
though formation of these adducts is reversible. No covalent
adducts were observed on reaction with E3330, even after a 2-
h reaction. Similar results were observed when the reactions
were performed with APE1 delta 40 and either E3330 or
the analogues (Fig. 9). These results can be explained by the
mechanism shown in Fig. 8B. Reaction of a protein thiolate
with the quinone moiety generates the Michael adduct from
both structures. In the cases of RN7-60 and RN10-52, the
chlorine substituent provides a good leaving group, and its
expulsion from the intermediate leads to the covalent adduct.
In the case of RN8-51, however, themethoxy group is a poorer
leaving group than the protein thiolate; the reaction reverts,
and the modifications by RN8-51 are reversible.
These data led us to a number of conclusions on the
mechanism of action for APE1 redox function and hypotheses
concerning the interaction of APE1 with E3330 and the ana-
logues presented in this article. Two of the analogues, RN10-
52 and RN7-60, are quite reactive and readily form covalent
adducts, resulting inmodification not only of the two solvent-
accessible but also of the five remaining interior Cys residues
in APE1. These results suggest that RN7-60 and RN10-52
cause at least partial unfolding of the enzyme, exposing bur-
ied Cys residues. These two analogues were found to induce
apoptosis atmuch higher levels than observed for RN8-51 and
E3330. In contrast, RN8-51 appears to form reversible adducts
with solvent-accessible Cys residues when incubated with
APE1 (Fig. 10). E3330 may also react reversibly, but no ad-
ducts were observed under these conditions. Thus, we iden-
tified in this analysis a second promising APE1 redox
inhibitor, RN8-51, and validated that targeting the APE1 re-
dox activity shows promise for further translational antican-
cer therapeutic development.
In conclusion, the studies presented here represent addi-
tional progress toward understanding the mechanism of redox
regulation of the unique multifunctional DNA-repair and
redox-signaling molecule, APE1. We also show further data of
biologic relevance of our laboratories’ recently synthesized
new and novel compounds that have anti-APE1 redox activity
(22). Several significant findings have resulted from the studies
presented here, indicating that (a) inhibition of the APE1 redox
activity shows potential for therapeutic development, and (b)
a promising new analogue of E3330 has been identified.
Additionally, current work in our laboratories on the redox
mechanism of APE1 is in progress, and we anticipate charac-
terizing a novel redox mechanism based on further analysis of
the interaction of E3330 with APE1.
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Abbreviations Used
AP¼ apurinic=apyrimidinic
APE1¼AP endonuclease 1
BER¼ base excision repair
CID¼ collision-induced dissociation
DTT¼dithiothreitol
EBM¼ endothelial basic medium
E. coli¼Escherichia coli
ECFC ¼ endothelial colony-forming cell
Egr-1 ¼ early growth response protein-1
EMSA ¼ electrophoretic mobility shift assay
FA ¼ formic acid
FL-APE1 ¼ full-length APE1
FT ¼ Fourier transform
HIF-1a ¼ hypoxia-inducible factor 1, alpha
subunit
IC50 ¼ half-maximal inhibitory concentration
LC-MS=MS ¼ liquid chromatography–tandem mass
spectrometry
LD50 ¼ lethal dose at 50% kill
MS=MS ¼ tandem mass spectrometry
NF-kB ¼ nuclear factor-kB
NF-kB Luc gene ¼ luciferase gene with
the NF-kB–responsive promoter
OD ¼ optical density
p53 ¼ protein 53
Redox ¼ reduction oxidation
Ref-1 ¼ redox effector factor 1
RVEC ¼ retinal vascular endothelial cells
SAR ¼ structure–activity relation
TF ¼ transcription factor
TUNEL ¼ TdT-mediated dUTP-fluorescein
nick-end labeling
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